Literature DB >> 1964075

Assembly of transcriptionally active chromatin in vitro: a possible role for topoisomerase II.

R Q To1, E B Kmiec.   

Abstract

Some models of in vitro chromatin assembly suggest a biphasic molecular mechanism. The first phase, nucleosome formation, is comprised of the formation of histone-DNA complexes which mature into a canonical nucleosome structure. The second phase represents the process by which these nucleosomes become properly spaced with a regular periodicity on the DNA. In this report, we examine the role of DNA topoisomerases in the latter phase of chromatin assembly. To study this process, we use a Xenopus laevis cell-free extract, which assembles quantitative amounts of chromatin on circular DNA templates, and the type II topoisomerase-specific antitumor drugs VM-26 and endrofloxicin. Our results suggest that nucleosome formation is unaffected by the presence of VM-26 or endrofloxicin. However, periodic spacing of nucleosomes is inhibited significantly by these drugs. In the absence of proper chromatin assembly, circular DNA molecules are processed into nucleoprotein complexes which are transcribed poorly. Taken together, these results indicate that the antitumor drugs VM-26 and endrofloxicin influence gene expression indirectly by blocking the periodic spacing of nucleosomes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964075

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  3 in total

1.  Interactions of Drosophila DNA topoisomerase II with left-handed Z-DNA in supercoiled minicircles.

Authors:  G C Glikin; T M Jovin; D J Arndt-Jovin
Journal:  Nucleic Acids Res       Date:  1991-12       Impact factor: 16.971

2.  Dexamethasone reverses glucocorticoid receptor RNA depression in multi-drug resistant (MDR) myeloma cell lines.

Authors:  L Danel-Moore; M Brönnegard; J A Gustafsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

3.  A 3' transcriptional enhancer regulates tissue-specific expression of the human CD2 gene.

Authors:  R A Lake; D Wotton; M J Owen
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.